Cologix Closes $525 Million USD Asset-Backed Securitization to Support AI Infrastructure, Interconnection and Growth
Cologix
, a leading network-neutral interconnection and hyperscale edge data center company in North America, today announced that it has closed a $525 million USD asset-backed securitization (ABS) to support the company's continued growth in digital infrastructure. The secured notes are backed by Cologix's
COL4 data center
in Columbus, Ohio, and structured with a five-year fixed term.
This transaction marks Cologix's fourth ABS issuance since 2021 and reflects the company's continued use of the asset-backed securities market to fund growth. Proceeds will support strategic investments across Cologix's Scalelogix℠ and Digital Edge portfolio, enabling the company to address increasing demand for inference AI and cloud workloads.
'This transaction demonstrates the strength of our balance sheet, the continued support of our investor base and the market's confidence in our long-term strategy,' said Scott Schneider, Chief Financial Officer of Cologix. 'As we kick off our next wave of growth, this financing will help us scale critical infrastructure to meet the increasing demands of hyperscale and inference AI applications.'
Cologix continues to expand its hyperscale edge footprint across North America, helping customers deploy cloud and AI-ready digital infrastructure at the network edge. This latest ABS financing follows three prior transactions in 2021, 2022 and 2023, further supporting the company's ability to scale critical infrastructure with speed and confidence.
'Our ability to deliver scalable, sustainable and deeply connected data center solutions is a key driver of customer success,' said Laura Ortman, Chief Executive Officer of Cologix. 'This financing ensures we're well-positioned to meet the needs of cloud providers, enterprise and AI customers seeking reliable, high-density interconnection at the edge.'
Cologix continues to prioritize operational sustainability in its growth strategy, maintaining average Power Usage Effectiveness (PUE) and Water Usage Effectiveness (WUE) rates that significantly outperform industry benchmarks. These efficiency measures reflect the company's commitment to responsible digital infrastructure development while scaling to meet future needs.
Deutsche Bank Securities Inc. served as the lead bank on the transaction and legal counsel was provided by King & Spalding.
About Cologix
Cologix powers digital infrastructure with 45+ hyperscale edge data centers and interconnection hubs across 12 North American markets, providing high-density, ultra-low latency solutions for cloud providers, carriers and enterprises. With AI-ready, industry-leading facilities, Cologix offers scalable, flexible and sustainable data center options to help its customers accelerate their business at the digital edge. Cologix provides extensive physical and virtual connections, including Access Marketplace, where customers gain fast, reliable and self-service provisioning for on-demand connectivity. For more information, visit
Cologix
or follow us on
and
X
.
Media Contact for Cologix:
Shifali Erasmus, Crackle PR
cologix@cracklepr.com
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/c3063352-433f-4899-b124-2c0792a7f0eb
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hamilton Spectator
3 hours ago
- Hamilton Spectator
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
VANCOUVER, British Columbia and BOSTON, Aug. 01, 2025 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced equity inducement grants to six new non-officer employees consisting of an aggregate of 24,200 share options. All of the foregoing share options were approved by the Compensation Committee of the Company's Board of Directors with an effective date of July 31, 2025 and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The share options have an exercise price of $30.54 per common share, which is equal to the closing price per share of Xenon's common shares on the grant date of July 31, 2025. The share option grants vest over four years, with 25% vesting on the one-year anniversary of the respective employee's start date and 1/36th of the remaining options vesting monthly thereafter on the last day of each month, subject to such option recipient's continued service relationship with the Company. Each option has a 10-year term and is subject to the terms and conditions of the share option agreement and the terms of the Company's 2025 Inducement Equity Incentive Plan. About Xenon Pharmaceuticals Inc. Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics. We are advancing an ion channel product portfolio to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. For more information, please visit . 'Xenon' and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner. Contacts: For Investors: Chad Fugere Vice President, Investor Relations (857) 675-7275 investors@ For Media: Colleen Alabiso Senior Vice President, Corporate Affairs (617) 671-9238 media@
Hamilton Spectator
3 hours ago
- Hamilton Spectator
Lumine Group Inc. Announces Results for the Three and Six Months Ended June 30, 2025
TORONTO, Aug. 01, 2025 (GLOBE NEWSWIRE) — Lumine Group Inc. ('Lumine Group' or 'the Company') (TSXV:LMN) announces financial results for the three and six months ended June 30, 2025. All amounts referred to in this press release are in US dollars unless otherwise stated. The following press release should be read in conjunction with the Company's unaudited condensed consolidated interim financial statements for the three and six months ended June 30, 2025, and management's discussion and analysis ('MD&A') for the three and six months ended June 30, 2025, which can be found on SEDAR+ at . Additional information about Lumine Group is also available on SEDAR+ and on Lumine Group's website . Q2 2025 Headlines: Year-to-Date Q2 2025 Headlines: Total revenue for the three months ended June 30, 2025 is $184.0 million, an increase of 13% or $21.1 million, compared to $162.8 million for the same period in 2024. For the six months ended June 30, 2025, total revenue was $362.6 million, an increase of 19%, or $58.7 million, compared to $303.9 million for the same period in 2024. The increase for the three and six months compared to the same period in the prior year is attributable to revenues from new acquisitions. The Company experienced organic growth of 9% and 2%, respectively, for the three and six months ended June 30, 2025, or 6% and 1% after adjusting for the impact of changes in the valuation of the US dollar against most major currencies in which the Company transacts business. For acquired companies, organic growth is calculated as the difference between actual revenues achieved by each business in the financial period following acquisition, compared to the estimated revenues they achieved in the corresponding financial period preceding the date of acquisition by the Company. Organic growth is not a standardized financial measure and might not be comparable to measures disclosed by other issuers. Operating income for the three months ended June 30, 2025 was $62.7 million, an increase of 71%, or $26.1 million, compared to $36.6 million for the same period in 2024. Operating income for the six months ended June 30, 2025 was $122.2 million, an increase of 51%, or $41.1 million, compared to $81.1 million for the same period in 2024. The increase for the three and six month periods is primarily attributable to growth from acquisitions. Operating income is not a standardized financial measure and might not be comparable to measures disclosed by other issuers. See 'Non-IFRS Measures'. Net income for the three months ended June 30, 2025 was $23.6 million compared to net loss of $2.2 million for the same period in 2024. Net income for the six months ended June 30, 2025 was $44.3 million compared to net loss of $306.6 million for the same period in 2024. The increase in net income for the three and six months is primarily attributable to growth from acquisitions and the Mandatory Conversion of Preferred and Special Securities on March 25, 2024 such that no further preferred and special securities expense was booked in the subsequent quarters. For the three months ended June 30, 2025, CFO increased $68.7 million to $78.4 million compared to $9.7 million for the same period in 2024 representing an increase of 705%. For the six months ended June 30, 2025, CFO increased $73.8 million to $118.5 million compared to $44.7 million for the same period in 2024 representing an increase of 165%. The primary reason for the increase is that CFO includes the impact of changes in non-cash operating assets and liabilities exclusive of effects of business combinations or changes in non-cash operating working capital ('NCOWC') which improved during the three and six months ended June 30, 2025 compared to the same period prior year, as well as higher operating income. For the three months ended June 30, 2025, FCFA2S increased $69.6 million to $72.4 million compared to $2.8 million for the same period in 2024. For the six months ended June 30, 2025, FCFA2S increased $75.8 million to $107.4 million compared to $31.5 million for the same period in 2024. The increase in the three and six months ended June 30, 2025 is driven by higher CFO compared to the same periods in 2024. FCFA2S is a non-IFRS Measure. See 'Non-IFRS Measures'. Non-IFRS Measures Operating income (loss) refers to income (loss) before income taxes, amortization of intangible assets, redeemable Preferred and Special Share expense, gain on bargain purchase, and finance and other expenses (income). We believe that operating income is useful supplemental information as it provides an indication of the profitability of the Company related to its core operations. Operating income (loss) is not a recognized measure under IFRS and may not be comparable to similar financial measures disclosed by other issuers. Accordingly, readers are cautioned that operating income (loss) should not be construed as an alternative to net income (loss). The following table reconciles operating income to net income: Free cash flow available to shareholders ''FCFA2S'' refers to net cash flows from operating activities less interest paid on lease obligations, interest paid on bank debt, transaction costs on bank debt, repayments of lease obligations, interest, dividends and other proceeds received, and property and equipment purchased net of proceeds from disposal. The Company believes that FCFA2S is useful supplemental information as it provides an indication of the uncommitted cash flow that is available to shareholders if Lumine Group does not make any acquisitions, or investments, and does not repay any debts. While the Company could use the FCFA2S to pay dividends or repurchase shares, the Company's objective is to invest all of its FCFA2S in acquisitions which meet the Company's hurdle rate. FCFA2S is not a recognized measure under IFRS and may not be comparable to similar financial measures disclosed by other issuers. Accordingly, readers are cautioned that FCFA2S should not be construed as an alternative to net cash flows from operating activities. The following table reconciles FCFA2S to net cash flows from operating activities: Forward Looking Statements Certain statements herein may be 'forward looking' statements that involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Lumine Group or the industry to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Forward looking statements involve significant risks and uncertainties, should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether or not such results will be achieved. A number of factors could cause actual results to vary significantly from the results discussed in the forward looking statements. These forward looking statements reflect current assumptions and expectations regarding future events and operating performance and are made as of the date hereof and Lumine Group assumes no obligation, except as required by law, to update any forward looking statements to reflect new events or circumstances. About Lumine Group Inc. Lumine Group acquires, strengthens, and grows, vertical market software businesses in the communications and media industry. Learn more at . For further information: David Nyland Chief Executive Officer Lumine Group investors@ +1-437-353-4910 Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Condensed Consolidated Interim Statements of Financial Position (In thousands of USD. Due to rounding, numbers presented may not foot.) Condensed Consolidated Interim Statements of Income (Loss) (In thousands of USD, except per share amounts. Due to rounding, numbers presented may not foot.) Condensed Consolidated Interim Statements of Comprehensive Income (Loss) (In thousands of USD. Due to rounding, numbers presented may not foot.) Condensed Consolidated Interim Statement of Changes in Equity (In thousands of USD. Due to rounding, numbers presented may not foot.) Condensed Consolidated Interim Statement of Changes in Equity (In thousands of USD. Due to rounding, numbers presented may not foot.) Condensed Consolidated Interim Statements of Cash Flows (In thousands of USD. Due to rounding, numbers presented may not foot.) 1 See 'Non-IFRS Measures'.
Yahoo
4 hours ago
- Yahoo
Cocoa Prices Sharply Lower on the Outlook for Adequate Supplies
September ICE NY cocoa (CCU25) on Friday closed down -274 (-3.22%), and September ICE London cocoa #7 (CAU25) closed down -165 (-2.92%). Cocoa prices settled sharply lower Friday as supply concerns eased on speculation that cocoa will be exempt from President Trump's tariffs. US Commerce Secretary Lutnick noted earlier this week that goods not produced in the US could be exempted from tariffs. More News from Barchart Brazil Tariff Risks Underpin Arabica Coffee Prices Arabica Coffee Rises as Tariff Risks Remain Cocoa Prices Settle Sharply Higher on Supply Woes Stop Missing Market Moves: Get the FREE Barchart Brief – your midday dose of stock movers, trending sectors, and actionable trade ideas, delivered right to your inbox. Sign Up Now! Earlier this week, cocoa prices rallied to 1-month highs on concern that the slowdown in the pace of Ivory Coast cocoa exports could tighten global supplies. Monday's government data showed that Ivory Coast farmers shipped 1.75 MMT of cocoa to ports this marketing year from October 1 to July 27, up +6.1% from last year but down from the much larger +35% increase seen in December. Concerns about dry weather in West Africa are also bullish for cocoa prices. According to the European Centre for Medium-Range Weather Forecasts, rainfall in the Ivory Coast and Ghana this season remains below the 30-year average, and combined with high temperatures, risks hurting cocoa pod development for the main crop harvest that starts in October. Concerns over tepid chocolate demand are bearish for cocoa prices. Last Tuesday, chocolate maker Lindt & Spruengli AG lowered its margin guidance for the year due to a larger-than-expected decline in first-half chocolate sales. Also, chocolate maker Barry Callebaut AG reduced its sales volume guidance earlier this month for a second time in three months, citing persistently high cocoa prices. The company projects a decline in full-year sales volume and reported a -9.5% drop in its sales volume for the March-May period, the largest quarterly decline in a decade. Cocoa prices sold off last month, with NY cocoa sinking to an 8.5-month nearest-futures low and London cocoa slumping to a 17-month nearest-futures low. Weakness in global cocoa demand has hammered prices. The European Cocoa Association reported on July 17 that Q2 European cocoa grindings fell by -7.2% y/y to 331,762 MT, a bigger decline than expectations of -5% y/y. Also, the Cocoa Association of Asia reported that Q2 Asian cocoa grindings fell -16.3% y/y to 176,644 MT, the smallest amount for a Q2 in 8 years. North American Q2 cocoa grindings fell -2.8% y/y to 101,865 MT, which was a smaller decline than the declines seen in Asia and Europe. In a bearish development, ICE-monitored cocoa inventories held in US ports reached a 10.5-month high of 2,368,141 bags last Tuesday. Higher cocoa production by Ghana is bearish for cocoa prices. On July 1, the Ghana Cocoa Board projected the 2025/26 Ghana cocoa crop would increase by +8.3% y/y to 650,000 from 600,000 MT in 2024/25. Ghana is the world's second-largest cocoa producer. Cocoa prices have support from quality concerns regarding the Ivory Coast's mid-crop cocoa, which is currently being harvested through September. Cocoa processors are complaining about the quality of the crop and have rejected truckloads of Ivory Coast cocoa beans. Processors reported that about 5% to 6% of the mid-crop cocoa in each truckload is of poor quality, compared with 1% during the main crop. According to Rabobank, the poor quality of the Ivory Coast's mid-crop is partly attributed to late-arriving rain in the region, which limited crop growth. The mid-crop is the smaller of the two annual cocoa harvests, which typically starts in April. The average estimate for this year's Ivory Coast mid-crop is 400,000 MT, down -9% from last year's 440,000 MT. On May 30, the International Cocoa Organization (ICCO) revised its 2023/24 global cocoa deficit to -494,000 MT from a February estimate of -441,000 MT, the largest deficit in over 60 years. ICCO said 2023/24 cocoa production fell by 13.1% y/y to 4.380 MMT. ICCO stated that the 2023/24 global cocoa stocks-to-grindings ratio declined to a 46-year low of 27.0%. Looking ahead to 2024/25, ICCO on February 28 forecasted a global cocoa surplus of 142,000 MT for 2024/25, the first surplus in four years. ICCO also projected that 2024/25 global cocoa production will rise +7.8% y/y to 4.84 MMT. On the date of publication, Rich Asplund did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
